NCT01413178 · OUTCOME

Progression-Free Survival (PFS)

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma · Source last updated 2020-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 3 years after transplant

What was measured

Participants that are still alive and without Multiple Myeloma 3 years after Stem cell Transplantation.

Groups in this outcome

Busulfan + Melphalan

Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant

Melphalan

High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Busulfan + Melphalan	104
Melphalan	98

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Busulfan + Melphalan	72	Not reported	Not reported	Not reported	Not reported
Melphalan	50	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
72
group Id
OG001
value
50

denoms

counts
group Id
OG000
value
104
group Id
OG001
value
98
units
Participants

description

Participants that are still alive and without Multiple Myeloma 3 years after Stem cell Transplantation.

groups

description
Busulfan with a target daily area under the curve (AUC) of 5000 with Melphalan 70 mg/m2 followed by a stem cell transplant
id
OG000
title
Busulfan + Melphalan
description
High-dose Melphalan 200 mg/m2/day followed by a stem cell transplant
id
OG001
title
Melphalan

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

3 years after transplant

title

Progression-Free Survival (PFS)

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice